BR112022015002A2 - Ligante de il-7r-alfa/gama/c, composto, composição farmacêutica, método para tratar uma doença em um paciente e ácido nucleico - Google Patents

Ligante de il-7r-alfa/gama/c, composto, composição farmacêutica, método para tratar uma doença em um paciente e ácido nucleico

Info

Publication number
BR112022015002A2
BR112022015002A2 BR112022015002A BR112022015002A BR112022015002A2 BR 112022015002 A2 BR112022015002 A2 BR 112022015002A2 BR 112022015002 A BR112022015002 A BR 112022015002A BR 112022015002 A BR112022015002 A BR 112022015002A BR 112022015002 A2 BR112022015002 A2 BR 112022015002A2
Authority
BR
Brazil
Prior art keywords
gamma
alpha
ligand
disease
patient
Prior art date
Application number
BR112022015002A
Other languages
English (en)
Inventor
J Dower William
C Needels Michael
W Barrett Ronald
V Bakker Alice
E Cwirla Steven
Original Assignee
Medikine Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medikine Inc filed Critical Medikine Inc
Publication of BR112022015002A2 publication Critical patent/BR112022015002A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5418—IL-7
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

LIGANTE DE IL-7R-alfa/gama/c, COMPOSTO, COMPOSIÇÃO FARMACÊUTICA, MÉTODO PARA TRATAR UMA DOENÇA EM UM PACIENTE E ÁCIDO NUCLEICO. São divulgados compostos de ligação de IL-7R-alfa/gama/c e composições farmacêuticas compreendendo os compostos de ligação de IL-7R-alfa/gama/c. Os compostos de ligação de IL7R-alfa/gama/c podem agir como agonistas de IL-7R e são úteis em tratamento de câncer, doenças virais, doenças autoimunes e doenças inflamatórias.
BR112022015002A 2020-02-03 2021-02-03 Ligante de il-7r-alfa/gama/c, composto, composição farmacêutica, método para tratar uma doença em um paciente e ácido nucleico BR112022015002A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062969432P 2020-02-03 2020-02-03
US202063041158P 2020-06-19 2020-06-19
PCT/US2021/016361 WO2021158623A1 (en) 2020-02-03 2021-02-03 IL-7Rαγc BINDING COMPOUNDS

Publications (1)

Publication Number Publication Date
BR112022015002A2 true BR112022015002A2 (pt) 2022-12-06

Family

ID=77200524

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022015002A BR112022015002A2 (pt) 2020-02-03 2021-02-03 Ligante de il-7r-alfa/gama/c, composto, composição farmacêutica, método para tratar uma doença em um paciente e ácido nucleico

Country Status (12)

Country Link
US (2) US11746139B2 (pt)
EP (1) EP4100427A4 (pt)
JP (1) JP2023514128A (pt)
KR (1) KR20220139918A (pt)
CN (1) CN115315435A (pt)
AU (2) AU2021217353A1 (pt)
BR (1) BR112022015002A2 (pt)
CA (1) CA3166816A1 (pt)
IL (1) IL295304A (pt)
MX (1) MX2022009390A (pt)
TW (2) TW202342505A (pt)
WO (1) WO2021158623A1 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021001493A (es) 2018-08-06 2021-07-15 Medikine Inc Compuestos de fijación al receptor de il-2.
US11248030B2 (en) 2019-11-05 2022-02-15 Medikine, Inc. Dual IL-2R and IL-7R binding compounds
WO2021092075A1 (en) 2019-11-05 2021-05-14 Medikine Inc. IL-2RβγC BINDING COMPOUNDS
CN115297886A (zh) * 2020-02-03 2022-11-04 麦地金公司 IL-7Rα结合化合物
CN115315435A (zh) 2020-02-03 2022-11-08 麦地金公司 IL-7Rαγc结合化合物
WO2023133595A2 (en) 2022-01-10 2023-07-13 Sana Biotechnology, Inc. Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
WO2023193015A1 (en) 2022-04-01 2023-10-05 Sana Biotechnology, Inc. Cytokine receptor agonist and viral vector combination therapies
US11999771B2 (en) 2022-04-07 2024-06-04 Medikine, Inc. IL-7Rαγc ligand immunoglobulin fusion proteins
WO2024054870A1 (en) 2022-09-06 2024-03-14 Medikine, Inc. Use of il-7r-alpha-gamma agonist peptides in cell manufacturing
WO2024054874A1 (en) 2022-09-06 2024-03-14 Medikine, Inc. Use of il-2r-beta-gamma agonist peptides in cell manufacturing

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5635597A (en) 1994-05-27 1997-06-03 Affymax Technologies, N.V. Peptides that bind IL-2 receptors
EP2354791A1 (en) 2001-12-04 2011-08-10 Merck Patent GmbH Immunocytokines with modulated selectivity
US20050054054A1 (en) * 2002-11-12 2005-03-10 Foss Francine M. Interleukin-7 molecules with altered biological properties
ATE393169T1 (de) 2003-12-30 2008-05-15 Merck Patent Gmbh Il-7-fusionsproteine mit antikörperportionen, deren herstellung und deren verwendung
ATE465176T1 (de) 2004-12-09 2010-05-15 Merck Patent Gmbh Il-7-varianten mit reduzierter immunogenität
US20090104218A1 (en) 2004-12-22 2009-04-23 J. Craig Venter Institute Group B Streptococcus
WO2010099084A2 (en) 2009-02-27 2010-09-02 Monsanto Technology Llc Isolated novel nucleic acid and protein molecules from corn and methods of using those molecules
IL226267B (en) 2010-11-12 2022-09-01 Nektar Therapeutics Conjugations of a part of il-2 and a polymer, preparations containing them and their uses
CA2820956C (en) * 2010-12-10 2016-05-03 University Of Central Florida Research Foundation, Inc. Methods and compositions comprising il-7 receptor ligands
WO2012099886A1 (en) 2011-01-18 2012-07-26 Bioniz, Llc Compositions and mehthods for modulating gamma-c-cytokine activity
CA2946398A1 (en) 2014-04-24 2015-10-29 The Board Of Trustees Of The Leland Stanford Junior University Superagonists, partial agonists and antagonists of interleukin-2
DK3172227T3 (da) 2014-07-21 2019-12-02 Delinia Inc Molekyler der selektivt aktiverer regulatoriske t-celler til behandlingen af autoimmune sygdomme
ES2717831T3 (es) 2014-08-11 2019-06-25 Delinia Inc Variantes de IL-2 modificadas que activan selectivamente las células T reguladoras para el tratamiento de enfermedades autoinmunes
CN115925939A (zh) 2015-08-06 2023-04-07 新加坡科技研究局 IL2Rβ/通用γ链抗体
MA45488A (fr) 2015-10-22 2018-08-29 Juno Therapeutics Gmbh Procédés, kits et appareil de culture de cellules
US20170204154A1 (en) 2016-01-20 2017-07-20 Delinia, Inc. Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
EP3411414A4 (en) 2016-02-05 2019-10-23 Washington University COMPOSITIONS AND METHOD FOR TARGETED CYTOKINE RELIEF
CA3041334A1 (en) 2016-11-08 2018-05-17 Delinia, Inc. Il-2 variants for the treatment of autoimmune diseases
TWI777996B (zh) 2016-12-09 2022-09-21 法商Ｏｓｅ免疫療法公司 靶向ｃｄ１２７之抗體和多肽
CA3044416A1 (en) 2016-12-13 2018-06-21 Delinia, Inc. Multivalent regulatory t cell modulators
MX2021001493A (es) 2018-08-06 2021-07-15 Medikine Inc Compuestos de fijación al receptor de il-2.
WO2020247388A2 (en) 2019-06-03 2020-12-10 Medikine, Inc. Il-2alpha receptor subunit binding compounds
US20220119492A1 (en) 2019-11-05 2022-04-21 Medikine, Inc. Il-2r-beta-gamma binding compounds and uses thereof
WO2021092075A1 (en) 2019-11-05 2021-05-14 Medikine Inc. IL-2RβγC BINDING COMPOUNDS
US11248030B2 (en) 2019-11-05 2022-02-15 Medikine, Inc. Dual IL-2R and IL-7R binding compounds
AU2020406083A1 (en) 2019-12-17 2022-06-16 Boehringer Ingelheim International Gmbh Bifunctional molecules comprising an IL-7 variant
CN115315435A (zh) 2020-02-03 2022-11-08 麦地金公司 IL-7Rαγc结合化合物
CN115297886A (zh) 2020-02-03 2022-11-04 麦地金公司 IL-7Rα结合化合物
EP4268901A3 (en) 2020-11-04 2024-01-17 Medikine, Inc. Il-2r beta-gamma c binding compounds and uses thereof
US11999771B2 (en) 2022-04-07 2024-06-04 Medikine, Inc. IL-7Rαγc ligand immunoglobulin fusion proteins

Also Published As

Publication number Publication date
MX2022009390A (es) 2022-11-16
CN115315435A (zh) 2022-11-08
JP2023514128A (ja) 2023-04-05
CA3166816A1 (en) 2021-08-12
US20210253670A1 (en) 2021-08-19
WO2021158623A1 (en) 2021-08-12
US11746139B2 (en) 2023-09-05
US11965015B2 (en) 2024-04-23
TW202342505A (zh) 2023-11-01
AU2024201860A1 (en) 2024-05-16
TW202144390A (zh) 2021-12-01
US20230357358A1 (en) 2023-11-09
TWI812918B (zh) 2023-08-21
EP4100427A4 (en) 2024-01-17
EP4100427A1 (en) 2022-12-14
AU2021217353A1 (en) 2022-08-25
IL295304A (en) 2022-10-01
KR20220139918A (ko) 2022-10-17

Similar Documents

Publication Publication Date Title
BR112022015002A2 (pt) Ligante de il-7r-alfa/gama/c, composto, composição farmacêutica, método para tratar uma doença em um paciente e ácido nucleico
BR112022008744A2 (pt) Ligante de il-2rss, ligante de il-2r¿c, composto de ligação a il-2r¿¿c, composição farmacêutica, método para tratar uma doença em um paciente, método para expandir células imunes, método de uma terapia celular, método para reforçar uma vacina, método para modificar a resposta imune e ácido nucleico
BR112022008750A2 (pt) Composto de ligação de receptor duplo, composição farmacêutica, método para tratar uma doença em um paciente, método para expandir células imunes, método para reforçar uma vacina, método para modificar a resposta imune e ácido nucleico
BR112021024674A2 (pt) Derivado heterocíclico de nitrogênio com cinco membros de pirimidina, método de preparação do mesmo e uso farmacêutico do mesmo
BRPI0622054B8 (pt) composto e composição farmacêutica
EA201991399A1 (ru) Аминотриазолопиридиновые соединения и их применение в лечении рака
JOP20200315A1 (ar) مركبات بورينون واستخدامها في معالجة السرطان
BR112022001324A2 (pt) Composto, composição farmacêutica e método para tratamento de uma doença mediada por p38 map quinase em um indivíduo necessitando do mesmo
EA200700501A1 (ru) Композиция (варианты) и способ для лечения гиперпролиферативных процессов, способ лечения рака (варианты) и способ получения твёрдой дисперсии вещества
EA201590855A1 (ru) Соединения пирролопиримидина как ингибиторы киназ
BR112021025928A2 (pt) Métodos de preparação de ácido bempedoico e composições do mesmo
BR112014018728A8 (pt) Compostos de purinonas como inibidores de quinase
ECSP066833A (es) Compuestos heterocíclicos anticitocina
BR112021021224A2 (pt) Anticorpos ou fragmentos de anticorpos, composição farmacêutica, kit, ácido nucleico ou conjunto de ácidos nucleicos, célula hospedeira recombinante e método para o tratamento ou a prevenção de uma doença em um paciente em necessidade do mesmo
EA201500373A1 (ru) Маситиниб или его соль для лечения рака, фармацевтическая композиция, лекарственное средство и набор
EA201791535A1 (ru) Новое соединение 4'-тионуклеозида, а также способ его получения, его фармацевтическая композиция и применение
AR120223A1 (es) Proteínas que unen nkg2d, cd16 y flt3
EA201001196A1 (ru) Соединения 4-пиридинона и их применение для лечения рака
BR112022024483A2 (pt) Métodos para tratar mieloma múltiplo
DE602004018788D1 (de) Faktor-ixa-spezifische antikörper, die faktor-viiia-ähnliche wirkung zeigen
BR112020024412A8 (pt) Anticorpos, composição farmacêutica, kit, ácido nucleico, célula hospedeira, métodos de tratamento ou prevenção de câncer, de redução da atividade, de aumento da atividade e de aumento da ativação
BR112017026535A2 (pt) composto de fórmula estrutural i, enantiômero isolado, composição farmacêutica, método para inibir atividade do transportador de monocarboxilato mct4, método para inibir seletivamente atividade do transportador de monocarboxilato mct4, método para tratar um distúrbio mediado por transportador de monocarboxilato mct4 e uso de um composto
PH12020500666A1 (en) Pladienolide compounds and their use
MX2020002429A (es) Compuestos para reducir la viscosidad de las formulaciones biologicas.
BR112022026550A2 (pt) Composição de compostos que modulam o metabolismo celular e métodos de uso